599 related articles for article (PubMed ID: 32885754)
41. Screening of Antitubercular Compound Library Identifies Inhibitors of Mur Enzymes in
Eniyan K; Rani J; Ramachandran S; Bhat R; Khan IA; Bajpai U
SLAS Discov; 2020 Jan; 25(1):70-78. PubMed ID: 31597510
[TBL] [Abstract][Full Text] [Related]
42. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis.
Prabu A; Hassan S; Prabuseenivasan ; Shainaba AS; Hanna LE; Kumar V
J Mol Graph Model; 2015 Sep; 61():133-40. PubMed ID: 26245695
[TBL] [Abstract][Full Text] [Related]
43. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
[TBL] [Abstract][Full Text] [Related]
44. DprE1--from the discovery to the promising tuberculosis drug target.
Mikusová K; Makarov V; Neres J
Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
[TBL] [Abstract][Full Text] [Related]
45. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
46. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
47. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
Tripathi A; Wadia N; Bindal D; Jana T
Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
[TBL] [Abstract][Full Text] [Related]
48. In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs.
Santos P; López-Vallejo F; Soto CY
Chem Biol Drug Des; 2017 Aug; 90(2):175-187. PubMed ID: 28111912
[TBL] [Abstract][Full Text] [Related]
49. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
50. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
51. Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.
Whitehurst BC; Young RJ; Burley GA; Cacho M; Torres P; Vela-Gonzalez Del Peral L
Bioorg Med Chem Lett; 2020 Jun; 30(12):127192. PubMed ID: 32312582
[TBL] [Abstract][Full Text] [Related]
52. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
53. Microbiology. TB--a new target, a new drug.
Cole ST; Alzari PM
Science; 2005 Jan; 307(5707):214-5. PubMed ID: 15653490
[No Abstract] [Full Text] [Related]
54.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
[TBL] [Abstract][Full Text] [Related]
56. Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds.
Santos P; Lopez-Vallejo F; Ramírez D; Caballero J; Mata Espinosa D; Hernández-Pando R; Soto CY
Bioorg Med Chem; 2020 Feb; 28(3):115256. PubMed ID: 31879181
[TBL] [Abstract][Full Text] [Related]
57. New and Old Hot Drug Targets in Tuberculosis.
Chiarelli LR; Mori G; Esposito M; Orena BS; Pasca MR
Curr Med Chem; 2016; 23(33):3813-3846. PubMed ID: 27666933
[TBL] [Abstract][Full Text] [Related]
58. In vitro activity of collinin isolated from the leaves of Zanthoxylum schinifolium against multidrug- and extensively drug-resistant Mycobacterium tuberculosis.
Kim S; Seo H; Mahmud HA; Islam MI; Lee BE; Cho ML; Song HY
Phytomedicine; 2018 Jul; 46():104-110. PubMed ID: 30097109
[TBL] [Abstract][Full Text] [Related]
59. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.
Vilchèze C; Baughn AD; Tufariello J; Leung LW; Kuo M; Basler CF; Alland D; Sacchettini JC; Freundlich JS; Jacobs WR
Antimicrob Agents Chemother; 2011 Aug; 55(8):3889-98. PubMed ID: 21628538
[TBL] [Abstract][Full Text] [Related]
60. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.
Niehaus AJ; Mlisana K; Gandhi NR; Mathema B; Brust JC
PLoS One; 2015; 10(9):e0135003. PubMed ID: 26332235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
